Navigation Links
AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September
Date:9/15/2011

REDWOOD CITY, Calif., Sept. 15, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences in New York City over the coming weeks as follows:

UBS Global Life Sciences Conference

Date:  Tuesday, September 20th at 7:30 AM EST

Location:  Grand Hyatt New York

Webcast link:  http://cc.talkpoint.com/ubsx001/091911a_im/?entity=109_C624HWQ

The Sixth Annual JMP Securities Healthcare Conference

Date:  Wednesday, September 28th at 11:00 AM EST

Location:  The St. Regis New York

Webcast link:  http://wsw.com/webcast/jmp14/acrx/

Both presentations will be webcast live and can be accessed through the links above.  For those not available to listen to the live broadcast, the presentations will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the second half of 2011 under a grant from the US Army Medical Research and Material Command.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
2. AcelRx Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
3. AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results
4. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
5. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
6. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
7. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
11. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Fla. , Feb. 20, 2017   ... helping physicians diagnose and treat patients with cardiovascular ... provide wireless connectivity for ZywiePro, Zywie,s cardiac remote ... AT&T Control Center . AT&T and ... monitoring for those with the disease. The Internet ...
(Date:2/20/2017)... 20, 2017 Seal Shield LLC ( ... for mobile device management and disinfection, the ElectroClave™, to ... Exhibition in Orlando, Fla. from ... devices have become commonplace in today,s healthcare landscape, but ... of concerns, including the disinfection and tracking of these ...
(Date:2/20/2017)... DUBLIN , Feb. 20, 2017 Research ... Blood Refrigerator and Freezer Market Analysis and Trends - Product (RFID ... - Forecast to 2025" report to their offering. ... The Global RFID Blood ... of around 21.3% from 2015 to 2025. This ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 2017 , ... Nancy Johnston Toll marks her debut in the ... the Bump in the Road ” (published by Xlibris). Inspired from her personal experiences, ... the ups and downs experienced by anyone going through cancer treatment and how one ...
(Date:2/20/2017)... ... 2017 , ... Silverado today is pleased to announce that it has entered ... care community in Alexandria, Virginia. The new community is expected to open its doors ... , The three-story community with underground parking – located on King Street –will ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of touch ... 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... announced Biscom Document Router (BDR), the first IoT device from Biscom designed to ... imaging. Biscom will debut BDR at HIMSS17 and will be conducting ...
Breaking Medicine News(10 mins):